Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
SAN DIEGO, Oct. 18, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its third quarter 2017 financial results after the market closes on Wednesday, October 25, 2017 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 9042599. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on October 25, 2017 to 7:30 p.m. ET on November 1, 2017. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 9042599.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
